Page 125 - அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A Deep Dive On mRNA Vaccines February 11, 2021 By Deborah Borfitz February 11, 2021 | Messenger RNA (mRNA) vaccines were the focus of a symposium on COVID-19 vaccines held during last week’s COVID-19 and Cancer virtual meeting of the American Association for Cancer Research. To date, only two vaccines have received Emergency Use Authorization by the U.S. Food and Drug Administration and both are mRNA vaccines one developed by Moderna and the other by Pfizer and BioNTech. Speaking on development of the Moderna vaccine was Randall N. Hyer, M.D., Ph.D., the company’s senior vice president of global medical affairs. Michela Locci, Ph.D., assistant professor of microbiology at the University of Pennsylvania, presented on the ability of mRNA vaccines to elicit potent germinal center (GC) responses associated with neutralizing antibody generation. This was followed by a lively Q&A session moderated by Deepta Bhattacharya, Ph.D., a member of the cancer biology

South africaUnited statesRandalln hyerDeborah borfitzDeepta bhattacharyaMichela locciAmerican association for cancer researchNational cancer instituteUniversity of arizona cancer centerDrug administrationUniversity of pennsylvaniaAmerican associationEmergency use authorizationUarizona cancerNational cancerஒன்றுபட்டது மாநிலங்களில்